Table. Antimicrobial drug resistance among frequently isolated bacterial isolates from Syrian patients with war-associated wound infections, August 2011–March 2013*.
| Antimicrobial drug | No. MDR resistant isolates/no. total (%) |
|||
|---|---|---|---|---|
| Staphylococcus aureus, N = 19 | Pseudomonas aeruginosa, N = 10 | Escherichia coli, N = 8 | Acinetobacter baumannii, N = 6 | |
| Amikacin | 1/ 11 (9) | 1/7 (14) | 6/6 (100) | |
| Ampicillin | 5/5 (100) | |||
| Amoxicillin/clavulanic acid | 6/6 (100) | |||
| Cefotaxime | 6/8 (75) | |||
| Ceftriaxone | 5/8 (62) | |||
| Ceftazidime | 3/9 (33) | 5/8 (62) | 4/4 (100) | |
| Cefepime | 5/8 (62) | 5/5 (100) | ||
| Cefixime | 5/8 (62) | 5/5 (100) | ||
| Ciprofloxacin | 7/17 (41) | 5/8 (62) | 2/7 (28) | 5/5 (100) |
| Colistin | NA | NA | 0/5 | |
| Trimethoprim/sulfamethoxazole | 3/14 (21) | 3/5 (60) | ||
| Gentamicin | 10/18 (55) | 4/9 (44) | 4/8 (50) | 6/6 (100) |
| Piperacillin/tazobactam | 2/9 (22) | 3/7 (42) | NA | |
| Imipenem | 0/9 | 1/7 (14) | 4/5 (80) | |
| Penicillin | 9/10 (90) | |||
| Oxacillin | 7/17 (41) | |||
| Clindamycin | 9/17 (52) | |||
| Rifampin | 6/15 (40) | |||
| Fusidic acid | 10/15 (66) | |||
*Blank cells indicate that testing was not done.